Improving Cervical Cancer Screening Among the LGBT Community

Article

January is National Cervical Cancer Awareness Month, and until now, it has been a challenge for many in the lesbian, gay, bisexual, and transgender (LGBT) community to receive proper screening for various reasons.

The cure rate for cervical cancer is relatively high, but many women are still dying from the disease due to lack of screening and the ramped-up spread of HPV. This statistic may be even higher for women within the LGBT population.

Many LGBT individuals and their families face many barriers when it comes to healthcare and cancer prevention. The disparity and the risk exist for many reasons:

  • The ban on same-sex marriage in many states prevents individuals from obtaining health insurance through their partners.
  • Workplace discrimination causes people to be terminated and left with no health insurance.
  • Some healthcare professionals discriminate on the basis of the patient's sexual orientation.
  • Physicians and/or lesbians may not recognize the risk of contracting HPV from female partners.
  • STD information is not discussed enough within the LGBT community. Lesbians have higher prevalence of smoking and obesity.
  • Poor mental health due to continuing discrimination may deter many of these women from being screened.

Unfortunately, lesbians and bisexual women are 10 times less likely than heterosexual women to be screened for cervical cancer. But with the implementation of the Affordable Care Act (ACA), many women will be able to receive annual Pap smears, along with ongoing education.

The ACA will ensure that these women receive the necessary medical care so that:

  • Many LGBT individuals and their families have equal access to coverage.
  • Marketplaces use education, outreach, and enrollment strategies that are culturally competent and relevant for the LGBT community.
  • Marketplaces collect confidential demographic information about sexual orientation and gender identity and use it to serve the LGBT community better.

Do you find that the LGBT community is underserved when it comes to cancer prevention and screening? What has your facility done to make an impact?

References:

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content
Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers | Image Credit: © freshidea - stock.adobe.com.

Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers

April 24th 2024
Article

The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer

January 22nd 2024
Podcast

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Ixabepilone Combo Improves PFS/OS in Platinum-Resistant Ovarian Cancer

March 28th 2024
Article

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023
Podcast

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Nab-Sirolimus appears to produce responses in patients with perivascular epithelioid sarcoma regardless of TSC1/TSC2 mutation status.

Nab-Sirolimus Yields Sustained Responses in Gynecologic Sarcomas

March 20th 2024
Article

Nab-Sirolimus appears to produce responses in patients with perivascular epithelioid sarcoma regardless of TSC1/TSC2 mutation status.

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.

CRX100 Yields Responses, Tolerability in Platinum-Resistant Ovarian Cancer

March 19th 2024
Article

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.